Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients

Pediatric Nephrology

Volumn 11, Issue 3, 1997, Pages 318-321

  Kabasakul, S C ^a,b   Clarke, M ^a   Kane, H ^c   Karsten, J ^c   Clark, G ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b Department of Paediatrics ^*  (Turkey)

^c Sandoz Pharmaceutics UK Ltd   (United Kingdom)

Author keywords

Immunosuppression; Neoral; Pharmacokinetics; Renal transplantation; Sandimmun

Indexed keywords

CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; FOLLOW UP; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TIME;

AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; EMULSIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE;

EID: 0030906642     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050284     Document Type: Article

References (12)

1. Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15: 446 - 453
2. Kahan BD, Kramer WG, Wideman CA, Frazier OH, Lorber MI, Williams C, Flechner SM, Cooley DA, Van Buran CT (1986) Analysis of pharmacokmetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc 18: 115 - 119
3. Kahan BD, Grevel J (1988) Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631 - 644
4. Jacqz-Aigrain E, Montes C, Brun P, Loirat C (1994) Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children Eur J Clin Pharmacol 47: 61 - 65
5. Bökenkamp A, Offner G, Hoyer PF, Vester U, Wonigeit K, Brodehl J (1995) Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. Pediatr Nephrol 9: 196 - 198
6. Johnston A, Marsden JT, Hla KK, Henry JA, Holt DW (1986) The effect of vehicle on the oral absorption of cyclosporin Br J Clin Pharmacol 21: 331 - 333
7. Kahan BD, Kramer WG, Wideman C, Flechner SM, Larber MI, Van Buren CT (1986) Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41: 459 - 464
8. Kahan BD, Welsh M, Rutzky L, Lewis R, Knight R, Katz S, Napoli K, Grevel J, Van Buren CT (1992) The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 53: 345 - 351
9. Neumayer HH, Farber L, Haller P. Kohnen R, Maibaucher A, Schuster A, Vollmar J, Waiser J (1995) Clinical experience transferring kidney transplant patients from Sandimmun to Sandimmun Neoral - results after 3 months. Clin Nephrol 43 [Suppl]: S27 - S32
10. Keown PA, Stiller CR, Laupacis AL, Howson W, Coles R, Stawecki M, Koegler J, Carruthers G, McKenzie N, Sinclair NR (1982) The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 14: 659 - 661
11. Johnston A, Sketris I, Marsden JT, Galustrian CG, Fashola T, Taube D, Pepper J, Holt DW (1990) A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc 22: 1345 - 1346
12. Keown PA (1995) Pharmacokinetic, economic, and pharmacoepidemiologic analyses of Neoral in renal transplantation in Canada. In 'Neoral™: the new microemulsion formulation of cyclosporine. A roundtable discussion by Burke JF, Kahan BD, Pollak R, Frei U, Jamieson N, Keown PA World Medical Press, May 1995, [Suppl]